HPB : the official journal of the International Hepato Pancreato Biliary Association · 2025
Prognostic analysis of lymph node resection and liver resection for T1b and T2 gallbladder cancer: a multi-center retrospective study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Qiang, Li Yun-Cheng, You Ying-Nan, Li En-Shan, Liu Zeng-Li, Gao Yan-Chao, Sun Ke-Jian, Pan Guo-Zheng, Yu Da-Peng, Du Li-Xin, Du Yu-Han, Wang Xin, Zhang Tie-Zhong, Huang Shao-Hui, Liu Hui-Qiang, Hao Miao-Wang, Xu Yue-Xuan, Shi An-da, Shu Li-Zhuang, Zhao Li-Ming, Song Yan, Li Kang-Shuai, Zhang Zong-Li
Аннотация
BACKGROUND: Survival benefit of extended cholecystectomy including lymph node resection (LNR) and liver resection (LR) is still debating.
METHODS: Patients pathologically diagnosed with T1b and T2 stage GBC in 6 medical centers from 2012 to 2022 were included and retrospectively analyzed. Clinical variables, including patient characteristics, overall survival (OS), disease-free survival (DFS), surgical approaches, and adjuvant treatments were collected. Propensity score-matching was performed to compare the survival outcomes.
RESULTS: A total of 160 T1b/T2 GBC patients were included. 52 patients undergoing LNR were matched to 54 patients without LNR. After matching, LNR demonstrated significant survival benefit in OS (mOS 48.8 months vs not reached; p = 0.020) and DFS (mDFS 47.9 months vs 70.2 months; p = 0.038). Meanwhile, 61 patients undergoing LR were matched to 54 patients without LR. After matching, LR demonstrated no statistical difference in overall survival (mOS 68.2 months vs 78.5 months; p = 0.72) and disease-free survival (mDFS 67.1 months vs 42.6 months; p = 0.30).
CONCLUSIONS: Our results revealed that pathological T1b and T2 GBC patients benefit from radical cholecystectomy including lymph node resection and may not benefit from liver resection.
METHODS: Patients pathologically diagnosed with T1b and T2 stage GBC in 6 medical centers from 2012 to 2022 were included and retrospectively analyzed. Clinical variables, including patient characteristics, overall survival (OS), disease-free survival (DFS), surgical approaches, and adjuvant treatments were collected. Propensity score-matching was performed to compare the survival outcomes.
RESULTS: A total of 160 T1b/T2 GBC patients were included. 52 patients undergoing LNR were matched to 54 patients without LNR. After matching, LNR demonstrated significant survival benefit in OS (mOS 48.8 months vs not reached; p = 0.020) and DFS (mDFS 47.9 months vs 70.2 months; p = 0.038). Meanwhile, 61 patients undergoing LR were matched to 54 patients without LR. After matching, LR demonstrated no statistical difference in overall survival (mOS 68.2 months vs 78.5 months; p = 0.72) and disease-free survival (mDFS 67.1 months vs 42.6 months; p = 0.30).
CONCLUSIONS: Our results revealed that pathological T1b and T2 GBC patients benefit from radical cholecystectomy including lymph node resection and may not benefit from liver resection.